Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Safety and Efficacy of Different Doses of Intravenous APD405 for the Prevention of Post-Operative Nausea and Vomiting.
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2013
At a glance
- Drugs APD 405 (Primary)
- Indications Postoperative nausea and vomiting
- Focus Therapeutic Use
- 21 Apr 2012 Planned number of patients changed from 260 to 282 as reported by European Clinical Trials Database record.
- 24 Dec 2009 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
- 24 Dec 2009 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History